Cover Image


Cervical Cancer Drug Market & Pipeline Insight

出版商 PNS Pharma 商品編碼 317352
出版日期 內容資訊 英文 165 Pages
商品交期: 最快1-2個工作天內
Back to Top
子宮頸癌症治療藥市場與開發平台分析 Cervical Cancer Drug Market & Pipeline Insight
出版日期: 2014年06月01日 內容資訊: 英文 165 Pages



第1章 子宮頸癌症治療藥市場概要

  • 市場概要
  • 臨床實驗平台分析

第2章 子宮頸癌症臨床試驗分析,不同階段·各國

  • 前臨床
  • 臨床
  • 階段I
  • 階段I/II
  • 階段II
  • 階段III

第3章 已上市子宮頸癌症治療藥臨床分析及專利分析

第4章 中止及未開發的子宮頸癌症治療藥

  • 未開發
  • 中止

第5章 競爭情形

  • Advaxis
  • ApoVax
  • Genentech
  • GlaxoSmithKline
  • Inovio Pharmaceuticals
  • ISA Pharmaceuticals
  • 科研製藥
  • Merck



Cervical cancer is the third and fourth most common cause of cancer incidence and mortality among women across the world. Though there has been a decline in cervical cancer mortality rates in the previous few years, owing to early detection and intervention, challenges like over-diagnosis and over-treatment of the disease continue to remain. As per the World Health Organization (WHO), more than half a million new cases are diagnosed annually and there are close to 275,000 deaths every year. Thus, cervical cancer continues to be a major public health problem among the other cancers.

Significant amount of research is being undertaken to study the process of HPV infection causing precancerous changes in normal cells, which eventually leads to cervical cancer. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Once the results of these research activities are proved, there would be a major shift in the methods of treating this disease in the future.

Since there are no therapeutic vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. The current therapeutic vaccines have shown some systematic cellular immunity by intramuscular or subcutaneous injection. This has led the clinical trials to show cellular immune response to the vaccines. However, mucosal immunity at cervical mucosa is required and the pharma companies are currently focusing on this aspect. With the development of vaccines addressing this issue, there would be a significant reduction in the incidence rates of HPV across the globe.

Efforts are being made by the stakeholders to invest larger quantities of time and resources in obtaining a greater and deeper understanding of laboratory research which has indicated that HPVs (which are the major cause of cervical cancer), produce proteins which are called E5, E6, and E7. These proteins tend to interfere with the functions of the cells which normally prevent excessive growth. With a better knowledge of the mechanisms and working of these proteins, researchers could possibly be able to develop successful ways to limit the process by which HPV infection can lead to the growth of abnormal cells, thus controlling the incidence of cervical cancer.

"Cervical Cancer Drug Market & Pipeline Insight" Report Highlights:

  • Cervical Cancer Drug Market Overview
  • Marketed Drug Profiles & Patent Analysis
  • Clinical Trial Insight by Phase & Country
  • Drug in Clinical Development Phase: 47
  • Majority Drugs in Phase-II: 16
  • Marketed Cervical Cancer Drug: 6
  • Discontinued Drug Profiles: 26
  • Competitive Landscape

Table of Contents

1. Cervical Cancer Drug Market Overview

  • 1.1 Market Overview
  • 1.2 Clinical Pipeline Insight

2. Cervical Cancer Drug Clinical Trial Insight by Phase & Country

  • 2.1 Preclinical
  • 2.2 Clinical
  • 2.3 Phase I
  • 2.4 Phase I/II
  • 2.5 Phase II
  • 2.6 Phase III

3. Marketed Cervical Cancer Drug Clinical Insight & Patent Analysis

4. Discontinued & No Development Reported in Cervical Cancer Drug

  • 4.1 No Development Reported
  • 4.2 Discontinued

5. Competitive Landscape

  • 5.1 Advaxis
  • 5.2 ApoVax
  • 5.3 Genentech
  • 5.4 GlaxoSmithKline
  • 5.5 Inovio Pharmaceuticals
  • 5.6 ISA Pharmaceuticals
  • 5.7 Kaken Pharmaceutical
  • 5.8 Merck
  • Figure 1- 1: US - Number Cervical Cancer New Cases & Deaths, 2014
  • Figure 1- 2: Global Cervical Cancer Market (US$), 2013-2020
  • Figure 1- 3: Cervical Cancer Drugs in Pipeline by Phase (%), 2014
  • Figure 1- 4: Number of Cervical Cancer Drugs in Pipeline by Phase, 2014
  • Figure 1- 5: No Development in Cervical Cancer Drugs in Pipeline by Phase (%), 2014
  • Figure 1- 6: No Development in Cervical Cancer Drugs in Pipeline by Phase (Number), 2014
  • Figure 1- 7: Discontinued Cervical Cancer Drugs in Pipeline by Phase (%), 2014
  • Figure 1- 8: Number of Discontinued Cervical Cancer Drugs in Pipeline by Phase (%), 2014
  • Table 1-1: Europe - Cervical Cancer Estimated Incidence & Mortality by country, 2012

Following Information for Each Drug Profile is Covered in More than 200 Tables in Report:

  • Drug Profile Overview
  • Active Indication
  • Phase of Development
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class

List of Figures & Tables

Each Drug Profile has Tables Representing Following Information:

  • Alternate Names
  • Originator & Owner
  • Collaborator
  • Technology Provider
  • Licensee
  • Highest Development Phase
  • Indications
  • Class
  • Mechanism of Action
  • ATC Code
  • Designated Brand Name
Back to Top